New England Journal of Medicine MAY 29, 2014

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Talmadge E. King Jr., Williamson Z. Bradford, Socorro Castro-Bernardini, et al. (for the ASCEND Study Group)

Bottom Line

The ASCEND trial demonstrated that pirfenidone significantly reduced the rate of disease progression, as measured by forced vital capacity decline, in patients with idiopathic pulmonary fibrosis compared to placebo.

Key Findings

1. Pirfenidone treatment resulted in a 47.9% relative reduction in the proportion of patients who experienced an absolute decline in forced vital capacity (FVC) of ≥10% or death at 52 weeks (16.5% in the pirfenidone group vs. 31.8% in the placebo group; p<0.001).

2. There was a 132.5% relative increase in the proportion of patients with no decline in FVC (defined as change ≥0) in the pirfenidone group compared to placebo (22.7% vs. 9.7%; p<0.001).

3. Pirfenidone improved progression-free survival (hazard ratio 0.57; 95% CI, 0.43-0.77; p<0.001) and reduced the decline in 6-minute walk distance compared to placebo.

4. Adverse events, primarily gastrointestinal and skin-related (e.g., photosensitivity), were more common in the pirfenidone group but rarely led to treatment discontinuation (14.4% in the pirfenidone group vs. 10.8% in the placebo group).

Study Design

Design

RCT

Double-Blind

Sample

555

Patients

Duration

52 wk

Median

Setting

Multinational

Population Patients aged 40 to 80 years with a diagnosis of idiopathic pulmonary fibrosis (per ATS/ERS/JRS/ALAT criteria) of 6 to 48 months duration, with %FVC ≥50% and ≤90% and %DLCO ≥30% and ≤90%.

Intervention Oral pirfenidone (2,403 mg/day, administered as three capsules three times daily).

Comparator Matching placebo, administered three times daily.

Outcome Change in percent predicted forced vital capacity (FVC) from baseline to week 52, analyzed by a ranked ANCOVA model evaluating the proportion of patients with a ≥10% decline or death.

Study Limitations

• The study was not explicitly powered to detect statistically significant differences in all-cause mortality as a primary endpoint, though pooled analyses with previous trials suggested a benefit.

• The trial duration was limited to 52 weeks, restricting insights into long-term safety and efficacy beyond one year.

• The trial excluded patients with more severe lung function impairment, limiting the generalizability of results to those with advanced disease.

• Management of common side effects like gastrointestinal distress may influence adherence in real-world clinical practice compared to the controlled trial environment.

Clinical Significance

The ASCEND trial provided the definitive evidence required for FDA approval of pirfenidone, establishing it as a foundational, disease-modifying therapy capable of slowing the inevitable decline of lung function in patients with idiopathic pulmonary fibrosis.

Historical Context

Prior to this trial, the treatment landscape for idiopathic pulmonary fibrosis was characterized by a lack of approved therapies and inconclusive results from previous studies, including the earlier CAPACITY trials. The successful results of the ASCEND trial, in conjunction with the concurrent INPULSIS trials of nintedanib, marked a transformative milestone in IPF management.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the physiological rationale for using Forced Vital Capacity (FVC) as the primary endpoint in the ASCEND trial, and how does pirfenidone's proposed mechanism of action address the pathophysiology of Idiopathic Pulmonary Fibrosis (IPF)?

Key Response

IPF is characterized by progressive alveolar scarring and a restrictive ventilatory defect. FVC is the most reliable measure of lung volume in restrictive disease and a strong predictor of mortality. Pirfenidone is an oral antifibrotic agent that inhibits TGF-beta-induced collagen synthesis and decreases inflammation, directly targeting the pathways responsible for the fibroblastic foci formation that causes FVC decline.

Resident

A patient with IPF starting pirfenidone based on ASCEND trial evidence asks about potential side effects. Which specific adverse events were most frequent in the treatment group, and what clinical monitoring is mandatory for these patients?

Key Response

The ASCEND trial highlighted that gastrointestinal events (nausea, dyspepsia) and dermatologic events (photosensitivity rash) were significantly more common in the pirfenidone group. Clinically, residents must monitor liver function tests (ALT, AST, and bilirubin) monthly for the first six months and then quarterly, as drug-induced liver injury is a known risk requiring dose adjustment or discontinuation.

Fellow

The ASCEND trial utilized a 'rank-sum' analysis as its primary statistical approach. Why was this methodology chosen over a simple mean change in FVC, and how did the inclusion criteria for ASCEND differ from the previous CAPACITY trials to ensure a more definitive result?

Key Response

The rank-sum analysis (Salsburg method) was used to account for deaths; patients who died were assigned the worst possible rank, preventing the survival bias inherent in only measuring FVC in survivors. ASCEND also refined inclusion criteria (restricting to FVC 50-80% and DLCO 30-90%) to 'enrich' the population for those most likely to show measurable disease progression, correcting for the high number of stable patients in CAPACITY that diluted the earlier treatment signal.

Attending

The ASCEND trial demonstrated a 47.9% reduction in the proportion of patients with a decline of 10 percentage points or more in FVC. How does this 'physiologic stabilization' translate to long-term clinical outcomes like mortality, and how should this influence the timing of treatment initiation in asymptomatic patients?

Key Response

While ASCEND was not powered for mortality as a primary endpoint, a pre-specified pooled analysis of ASCEND and CAPACITY showed a significant reduction in all-cause and IPF-related mortality. The teaching point is that since we cannot reverse existing fibrosis, 'waiting for decline' results in the permanent loss of lung function; therefore, treatment should be initiated at diagnosis regardless of symptom severity to preserve maximum baseline FVC.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the use of a 10% absolute decline in FVC as a surrogate endpoint in ASCEND. Does this threshold represent a 'Minimum Clinically Important Difference' (MCID), and what are the statistical implications of using categorical 'responders' versus continuous slope analysis in IPF clinical trials?

Key Response

A 10% FVC decline is widely accepted as a predictor of mortality in IPF, making it a robust surrogate. However, using it as a categorical threshold (decline vs. no decline) can lose statistical power compared to longitudinal slope models (Random Coefficients Models). Ph.D. researchers focus on whether the treatment benefit is a uniform shift in the population or driven by preventing 'rapid progressors,' which has implications for the trial's generalizability and the biology of the drug's effect.

Journal Editor

If you were reviewing the ASCEND manuscript, how would you evaluate the impact of the 15% patient discontinuation rate on the trial's internal validity, and what specific sensitivity analyses would you demand to ensure the results aren't skewed by informative censoring?

Key Response

A tough reviewer would flag that patients dropping out due to side effects (informative censoring) might have also been the ones with the worst (or best) lung function. Editors look for sensitivity analyses such as 'last observation carried forward' (LOCF) or multiple imputation compared to the primary rank-sum analysis to ensure that the treatment effect remains significant even under conservative assumptions regarding missing data.

Guideline Committee

How did the results of the ASCEND trial alter the strength of recommendation for pirfenidone in the ATS/ERS/JRS/ALAT clinical practice guidelines, and how does the evidence level compare to other available therapies like nintedanib or NAC/Azathioprine/Prednisone (PANTHER-IPF)?

Key Response

Following ASCEND and the INPULSIS trials, guidelines moved to a 'Strong' recommendation for pirfenidone and nintedanib (Level of Evidence: High). This was a major shift from previous 2011 guidelines which offered a 'Weak' recommendation for pirfenidone. Crucially, ASCEND's success, contrasted with the PANTHER-IPF trial (which showed increased mortality with triple therapy), solidified the shift toward targeted antifibrotics as the standard of care over traditional immunosuppression.

Clinical Landscape

Noteworthy Related Trials

2010

CAPACITY Trial

n = 779 · Lancet

Tested

Pirfenidone

Population

Patients with idiopathic pulmonary fibrosis

Comparator

Placebo

Endpoint

Change in percent predicted forced vital capacity (FVC)

Key result: One of the two trials showed a significant reduction in FVC decline, while the other did not meet its primary endpoint, leading to further investigation in ASCEND.

2012

PANTHER-IPF Trial

n = 341 · NEJM

Tested

Prednisone, azathioprine, and N-acetylcysteine

Population

Patients with idiopathic pulmonary fibrosis

Comparator

Placebo

Endpoint

Death or hospitalization

Key result: Triple therapy was associated with an increased risk of death and hospitalization compared to placebo, leading to early termination of this treatment arm.

2014

INPULSIS-1 and INPULSIS-2 Trials

n = 1066 · NEJM

Tested

Nintedanib 150mg twice daily

Population

Patients with idiopathic pulmonary fibrosis

Comparator

Placebo

Endpoint

Annual rate of decline in forced vital capacity (FVC)

Key result: Nintedanib significantly slowed disease progression by reducing the annual rate of decline in FVC compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis